trending Market Intelligence /marketintelligence/en/news-insights/trending/3B5eO8tjUEu1mR_GghdLjg2 content esgSubNav
In This List

Emergent Biosolutions anthrax vaccine facility gets German regulatory approval

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Emergent Biosolutions anthrax vaccine facility gets German regulatory approval

Emergent BioSolutions Inc. received approval from the German Federal Ministry of Health unit Paul-Ehrlich-Institut for its large-scale manufacturing facility in Lansing, Mich., for the anthrax vaccine BioThrax.

The approval enables Emergent to market BioThrax in Germany.

BioThrax is the only anthrax vaccine licensed by the Paul-Ehrlich-Institut for pre-exposure prophylaxis of anthrax disease. It is also the only anthrax vaccine licensed by the U.S. FDA for both pre-exposure prophylaxis and post-exposure prophylaxis of anthrax disease.